Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Neurofibromatosis 1 1Neoplasm Metastasis 1Leukemia, Myelomonocytic, Juvenile 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Follicular 1

Interventions

vandetanib 7Sorafenib 6Magnetic Resonance Spectroscopy 6lenvatinib 5cabozantinib 5Sunitinib 4Iodine-131 4selpercatinib 3AZD 6244 3trametinib 2tipifarnib 2durvalumab 2dabrafenib 2alectinib 2Triiodothyronine 2Thyroxine 2Thyrotropin Alfa 2Paclitaxel 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Everolimus 2Bortezomib 2Axitinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tremelimumab 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Neoplasms × omipalisib × Clear all
NCT02152995 2026-04-13

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
34 enrolled 18 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡